Wolfram Carius (file photo)
December 7, 2020 06:39 AM EST
Deals
Cell/Gene Tx

Bay­er picks up off-the-shelf CAR-T ap­proach from Atara, spot­light­ing a Memo­r­i­al Sloan Ket­ter­ing break­through

Amber Tong

Bay­er’s brand new cell & gene ther­a­py strat­e­gy now al­so fea­tures CAR-T.

In a new deal with Atara Bio­ther­a­peu­tics, the Ger­man phar­ma has re­served …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

FDA says Ozem­pic, We­govy short­age is over

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times